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Fibrosis is characterized by the progressive alteration of the tissue structure
due to the excessive production of extracellular matrix (ECM). The signal-
ing system encompassing Receptor Activator of Nuclear factor NF-jB
Ligand (RANKL)/RANK/Osteoprotegerin (OPG) was discovered to play
an important role in the regulation of ECM formation and degradation in
bone tissue. However, whether and how this signaling pathway plays a role
in liver or pulmonary ECM degradation is unclear up to now. Interest-
ingly, increased decoy receptor OPG levels are found in fibrotic tissues. We
hypothesize that RANKL can stimulate RANK on macrophages and initi-
ate the process of ECM degradation. This process may be inhibited by
highly expressed OPG in fibrotic conditions. In this case, RANKL mutants
that can bind to RANK without binding to OPG might become promising
therapeutic candidates. In this study, we built a structure-based library
containing 44 RANKL mutants and found that the Q236 residue of
RANKL is important for OPG binding. We show that RANKL_Q236D
can activate RAW cells to initiate the process of ECM degradation and is
able to escape from the obstruction by exogenous OPG. We propose that
the generation of RANKL mutants with reduced affinity for OPG is a
promising strategy for the exploration of new therapeutics against fibrosis.
Introduction
The cytokine system consisting of receptor activator of
nuclear factor NF-jB ligand (RANKL), RANK and
Osteoprotegerin (OPG), plays a key role in bone
homeostasis by controlling the balance between bone
producing and bone resorbing activity [1]. RANKL is
expressed on osteoblasts and its receptor RANK is
expressed on osteoclast precursor cells [2]. As a mem-
ber of the tumor necrosis factor (TNF) superfamily,
RANKL is a type II transmembrane protein with a C-
terminal extracellular region [3–5]. The binding
between RANKL and RANK on osteoclast precursors
induces the expression of osteoclast-specific genes,
including tartrate-resistant acid phosphatase (TRAP),
cathepsin K, matrix metallopeptidase 9 (MMP9),
which will further trigger osteoclast maturation and
bone extracellular matrix (ECM) degradation [6,7].
Osteoprotegerin (OPG) is produced by osteoblasts and
acts as a natural decoy receptor for RANKL thereby
inhibiting osteoclast activation and bone ECM degra-
dation [8]. Imbalances in the RANK/RANKL/OPG
pathway can differently regulate the orientation of
bone remodeling to either bone formation or
Abbreviations
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resorption, therefore leading to diseases such as osteo-
porosis with a high RANKL/OPG ratio and osteopet-
rosis with a low RANKL/OPG ratio [9–12].
Fibrosis is a chronic disease characterized by exces-
sive accumulation of ECM and destruction of tissue
structure in response to injury [13,14]. With a high
mortality rate, fibrotic diseases cause more than
800 000 deaths every year worldwide [14]. However,
there is no effective therapy to reverse chronic fibrosis
currently. Taking pulmonary fibrosis as an example,
lung transplantation is the only effective way to treat
lung fibrosis at present [13,15,16]. Fibroblasts and
myofibroblasts are the most important cells involved
in the production of ECM [17]. Macrophages, which
are also abundantly present in fibrotic tissue, however,
have been shown to possess both profibrotic and
antifibrotic properties leading to different phenotypes
[18,19]. They have been identified to secrete inflamma-
tory and growth factors such as transforming growth
factor beta (TGF-b), IL-13 and TNF, which promote
the fibrotic process [14,15]. On the other hand, macro-
phages in fibrotic tissues also possess antifibrotic prop-
erties by producing secreted matrix metalloproteinases
(MMPs) and cathepsins that degrade fibrotic ECM
[20]. However, how antifibrotic macrophages are acti-
vated and induced to degrade ECM still remains to be
understood.
Interestingly, many tissue macrophages express
RANK, and through RANKL stimulation, proteases
are released which can degrade ECM [20]. In bone,
osteoclasts are derived from macrophage/monocyte
and can produce MMPs and other proteolytic enzymes
to degrade bone ECM [21,22]. In fibrotic tissue, the
stimulation of the RANKL/RANK axis may also be a
possible way to activate antifibrotic macrophages and
reverse fibrosis [20]. Notably, OPG, as a decoy recep-
tor of RANKL, was shown to be an inducer of fibro-
genesis to promote vascular fibrosis in vascular
smooth muscle cells [23]. High expression of OPG was
found to be related to the formation of fibrous tissues
in diseases like liver, vasculature, and cystic fibrosis
[24,25], suggesting that OPG may be important in the
fibrosis process, which is a further support for the a
role of the RANKL/RANK/OPG axis in fibrosis.
In the present research, we hypothesized that
RANKL could stimulate RANK on macrophages and
initiate the process of ECM degradation. This process
may be inhibited by the decoy activity of highly
expressed OPG in fibrotic conditions. As a conse-
quence, RANKL mutants that can bind to RANK
without binding to OPG are becoming promising ago-
nists to stimulate RANK on macrophages and reduce
ECM without being hampered by high OPG
production. Therefore, in this research, through com-
paring the 3D structures of murine RANKL–RANK
and RANKL–OPG, we have built a structure-based
RANKL mutants library containing 44 RANKL
mutants. Our results show that RANKL_Q236D is very
effective in activating murine RAW 264.7 macrophage
cells and to escape from the obstruction by exogenous
OPG. The generation of RANKL mutants with reduced
binding to OPG is a promising strategy for the explo-
ration of new therapeutics against fibrosis.
Results
RANKL–RANK- and RANKL–OPG-binding
interface analysis and structure-based design of
the mutants
The available 3D structures of murine RANKL–
RANK and RANKL–OPG complexes (Protein Data
Bank accession codes 4GIQ and 4E4D) were used to
perform binding simulations. As shown in Fig. 1A, via
analysis of all interactions—including hydrogen bonds,
electrostatic, and hydrophobic properties—between
RANKL–RANK and RANKL–OPG, all residues of
RANKL that show interactions with one or both
receptors were identified. These residues are marked
from light to dark purple according to the number of
interactions they were involved in (Fig. 1A).
RANKL_Q236, I248, and K256 were selected for
mutation because they show interactions with OPG,
but not RANK (Fig. 1B,C and Table 1). Therefore, it
is supposed that these can change the binding of
RANKL to OPG without influencing the binding of
RANKL to RANK. In addition, RANKL_R190,
R222, H252, and E268 were selected, because these
four residues show more interactions with OPG than
RANK (Fig. 1B,C and Table 1), suggesting that the
effect on RANKL–RANK interactions by replacing
them might be minimal.
In silico mutagenesis at positions Q236, I248, K256,
R190, R222, H252, and E268 was performed to esti-
mate differences between RANKL mutants and
RANKL_WT in DDGi binding to receptors (Fig. 2). A
more negative DDGi value indicates a predicted
increase in receptor binding energy, and vice versa.
Based on the outcome, we decided to select and con-
struct a subset of RANKL mutants. Two residues,
RANKL_Q236 and K256, were subjected to full satu-
ration mutagenesis, because for these two positions all
the other 19 amino acids were predicted to give a
decrease in affinity for OPG (Fig. 2A,B). Other single
substitutions of RANKL_I248W, H252W, H252L,
H252R, E268D, and E268N were selected on the basis
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of their predicted lowered affinity for OPG or their
large difference of predicted affinities for OPG and
RANK. In total 44 variants were proposed.
Prescreen of RANKL mutants with reduced
binding to OPG
After construction, expression, and purification using
cation exchange chromatography, 28 out of these 44
variants were obtained successfully. Most
RANKL_K256 variants, however, were produced in
inclusion bodies. On hindsight, this can be explained
by the role this residue plays in RANKL trimerization,
which forms a polar interaction with D303 within the
neighbor monomer [4]. Changing this lysine into any
other amino acid might prevent the formation of the
RANKL trimer. The double mutant RANKL_K256D/
D303K could not rescue the folding of the protein as
well. Apparently, no changes are tolerated at this posi-
tion and therefore the 256 variants were not used for
further investigations. To assess the binding of
RANKL variants to immobilized RANK-Fc and
OPG-Fc, an ELISA assay was performed (Fig. 3). Sev-
eral RANKL_236 variants RANKL_Q236N, Q236S,
Q236D, Q236H, Q236P, and Q236A showed an
increase in the binding ratio of RANK versus OPG.
Compared to RANKL_WT, they all showed higher
binding to RANK and 40–60% lower binding to
OPG. Especially, RANKL_Q236D was of interest as it
displayed a low binding to OPG, which is at 25% of
that of RANKL_WT. Variant RANKL_Q236K was
also selected for further analysis as it showed a large
decrease in binding to OPG with, however, a concomi-
tant lower ELISA signal in binding to RANK.
Receptor binding affinity of RANKL variants as
determined by SPR
Seven promising candidates, which maintained the
binding to RANK-Fc and showed decreased binding
to OPG-Fc were selected following the ELISA data.
These variants were purified to homogeneity as
described before [10]. Affinities of the purified
RANKL variants to RANK and OPG receptors were
determined using surface plasmon resonance (SPR).
By using the CM4 sensorchip, with a low density of
receptor, we were able to achieve complexes of
RANKL–RANK and RANKL–OPG in the form of
mixtures of trimer–monomer and trimer–dimer [26].
All the data were fitted with a 1 : 1 Langmuir fitting
model and the kinetic parameters were calculated and
shown in Table 2. All these seven RANKL mutants
showed much lower affinities to OPG-Fc with the best
one RANKL_Q236D showing around a three-time
Fig. 1. Structural comparison of RANKL/OPG and RANKL/RANK made using DISCOVERY STUDIO 4.5. (A) Structural comparison between RANKL/
OPG (upper sequence) and RANKL/RANK (bottom sequence). The color represents the residue shows interaction with receptor and the
range of color form light blue to dark blue indicates the number of interactions. (B, C) Detailed view of selected RANKL residues (R190,
R222, I248, Q236, H252, K256, and E268) and their interactions with OPG and RANK.
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decrease in the association rate constant (ka) and a 10-
fold increase in the dissociation rate constant (kd),
which taken together is a 30-time decrease in affinity
to OPG-Fc (Fig. 4). Importantly, this same mutant
maintained its affinity to RANK-Fc. RANKL_Q236K,
however, has a much lowered affinity to RANK-Fc as
suggested by its lower ELISA signal. RANKL mutants
Q236N, Q236S, Q236H, Q236P, and Q236A, all
showed affinities to RANK-Fc that are in the same
range or slightly lower than RANK_WT, between
50% and 100%, which is mainly due to higher dissoci-
ation rates. Taken together, these results are consistent
with the previous prescreen ELISA result and they fur-
ther confirm that the RANKL_Q236 residue indeed
plays an important role in RANKL–OPG binding
with RANKL_Q236D showing the most promising
properties.
Effect of RANKL variants on ECM degradation
enzymes expression in RAW 264.7 cells
In bone regulation process, the binding between
RANKL and the RANK on osteoclast precursors will
induce the expression of osteoclast-specific genes, such
as TRAP and MMP9, which will stimulate osteoclast
maturation and bone ECM degradation [22]. In fibro-
sis, MMPs have been shown to be responsible for col-
lagen degradation and ECM breakdown, which is
actually beneficial for fibrosis recovery [14,19]. Fur-
thermore, MMP9 is particularly expressed in
Table 1. Interaction analysis between RANKL–OPG and RANKL–RANK complexes.
RANKL–OPG RANKL–RANK
Interaction Category Interaction Category
K256 RANKL:K256:NZ–OPG1:E95:OE2 Electrostatic
RANKL:K256:HZ2–OPG1:E95:OE1 Hydrogen bond








H252 RANKL:H252:HD1–OPG1:S63:OG Hydrogen bond RANKL:H252:HE1–RANK1:Y47:OH Hydrogen bond
































RANKL:R222:HE–OPG2:E68:OE2 Hydrogen bond RANKL:R222:HD2–RANK2:G66:O Hydrogen bond
RANKL:R222:HH12–OPG2:E95:
OE1
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macrophages within lung and liver [20]. Therefore, we
chose a monocyte-derived RAW 264.7 macrophage as
a cell model to detect the biological effects caused by
RANKL variants. Real-time quantitative PCR was
performed to detect the TRAP and MMP9 gene
expressions in the presence of RANKL variants with
or without exogenous OPG. As shown in Fig. 5,
RANKL_WT (50 ngmL1) stimulation could signifi-
cantly induce the expressions of MMP9 and TRAP,
which was totally blocked by adding exogenous
mOPG-Fc at the concentration of 400 ngmL1. Inter-
estingly, the addition of mOPG-Fc did have much less
Fig. 2. Heatmap of the binding energy
predictions for RANKL_mutants. Predicted
differences in binding energy (DDGi) of
RANKL_K256, Q236, I248, R190, H252,
E268, and R222 variants binding to RANK
(A) and OPG (B) when compared with
RANKL_WT are shown in the heatmap
respectively. A negative DDGi value
indicates an improvement in receptor
binding, whereas a positive DDGi value
indicates a decrease in receptor binding.
Fig. 3. Comparison of the relative bindings
of RANKL mutants towards mOPG-Fc and
RANK-Fc, as determined by ELISA.
Receptor binding to mOPG-Fc and RANK-Fc
was performed in duplo and calculated
relative to the response of RANKL_WT
(100%) at 0.5 nM.
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influence on the activation by RANKL variants as
compared to that by RANKL_WT. Activation by
RANKL_Q236D was not inhibited at all by the pres-
ence of mOPG-Fc indicating that this variant is cap-
able of restoring MMP9 activity in fibrotic tissues.
Effect of RANKL variants on RANKL induced
osteoclastogenesis in RAW 264.7 cells
To further confirm the role of RANKL variants, we
next tested their effects on osteoclastogenesis in the
presence of mOPG-Fc. RAW 264.7 cells were treated
with RANKL_WT and variants with or without the
presence of mOPG-Fc. After 4 days, the cells were
measured for TRAP activity and osteoclasts forma-
tion, respectively. As shown in Fig. 6A,B,
RANKL_WT could significantly induce both TRAP
activation and osteoclast formation. This activation
was totally blocked by the addition of mOPG-Fc.
Treatments with RANKL variants Q236N, Q236S,
Q236H, Q236P, and Q236A could induce TRAP activ-
ity at a level comparable with RANKL_WT (Fig. 6A).
Interestingly, these RANKL variants exhibited less
inhibition by the addition of OPG-Fc and they were
capable to retain from 50% to 80% of TRAP activity
in the presence of OPG-Fc. RANKL_Q236K could no
longer induce TRAP activity because of its lower affin-
ity to RANK. Fascinatingly, RANKL_Q236D could
almost completely escape from the inhibition by OPG
and kept approximately 95% of TRAP activity. Con-
sistently, in the osteoclast formation assay (Fig. 6B),
RANKL_Q236N, Q236S, Q236H, Q236P, and Q236A
could only induce 18% to 54% of osteoclast formation
in the presence of 400 ngmL1 of mOPG-Fc, while
RANKL_Q236D still showed complete activation at
the same concentration of mOPG-Fc. Microscope pho-
tographs of osteoclasts from treatments with
RANKL_WT (50 ngmL1) and RANKL_Q236D
(50 ngmL1), both in the presence and absence of
mOPG-Fc are shown in Fig. 6C. Both single
treatments with RANKL_WT and RANKL_Q236D
instigated a massive osteoclast formation. The addition
of 400 ngmL1 of mOPG-Fc could completely block
osteoclast formation caused by RANKL_WT, but
showed no influence on that caused by
RANKL_Q236D.
Discussion
The RANKL/RANK/OPG system was discovered dec-
ades ago and is most prominently known for its role
in regulating bone density [27,28]. Nowadays this sys-
tem is known to be more versatile and is also thought
to be involved in the process of fibrosis [20,29,30].
High expression of OPG was found to be related to
fibrosis diseases like liver, vascular, and cystic fibrosis,
suggesting an important role of OPG in fibrosis [23–
25]. Recently, it was suggested that inefficient RANKL
stimulation occurs in lung tissues of human and mice
with pulmonary fibrosis [20] supporting the idea that
the decoy activity of OPG plays a role in fibrosis. In
this study, we hypothesized that RANKL could stimu-
late RANK on macrophages and initiate the process
of ECM degradation, which may be inhibited by high
OPG levels in fibrotic conditions. Therefore, RANKL
mutants, which can bind to RANK without binding to
OPG, are becoming of interest to solely stimulate
RANK on macrophages and reduce ECM without
binding to OPG present in fibrotic tissue. Notably,
OPG also acts as the decoy receptor of tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL), the
other member of the TNF superfamily, and recently a
TRAIL variant DHER lacking binding to OPG, was
developed [31,32], which indicates the possibility of
making RANKL variants as well.
The available 3D structures of murine RANKL–
RANK and RANKL–OPG complexes (Protein Data
Bank accession codes 4GIQ and 4E4D) were used as
the starting point for inspecting the binding surface.
Several residues of mRANKL, Q236, I248, K256,




7 (M1s1) kd 9 104 (s1) KD (pM) ka 9 106 (M1s1) kd 9 104 (s1) KD (pM)
RANKL_WT 1.8  0.7 0.7  0.1 4.3  1.6 8.4  0.6 1.0  0.1 11.9  1.5
RANKL_Q236N 1.5  0.2 3.1  0.9 20.7  3.7 7.9  0.9 1.7  0.3 22.1  2.9
RANKL_Q236H 1.3  0.2 2.2  0.5 16.6  1.6 6.7  0.0 1.3  0.2 18.7  2.8
RANKL_Q236S 1.4  0.2 3.1  0.4 23.3  4.5 7.0  0.6 1.8  0.5 24.9  5.1
RANKL_Q236D 0.6  0.1 7.0  1.0 112.3  24.4 6.4  0.8 0.9  0.2 15.0  3.2
RANKL_Q236A 1.6  0.3 3.3  0.4 20.5  2.2 8.9  2.0 1.8  0.3 21.5  6.6
RANKL_Q236K 1.1  0.5 14.6  2.7 142.7  44.6 8.0  1.3 9.5  0.8 119.3  10.5
RANKL_Q236P 1.1  0.3 2.2  0.3 21.3  8.2 6.1  0.5 1.2  0.4 19.8  6.0
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R190, R222, H252, and E268, stand out from the
analysis as they show more interactions with OPG
than RANK. In silico calculation of differences in
DDGi binding to receptors helped us to further reduce
the range of selection. The selected residues are located
in the C-D loop, D-E loop, E strand, and F strand of
RANKL, respectively. This is consistent with a previ-
ous analysis by Nelson et al. [33] that the contacts
made by OPG are limited to the E strand and D-E
loop region of RANKL. Upon expression, unfortu-
nately, RANKL K256 variants were not being prop-
erly folded and insoluble aggregates were formed. Lam
et al. [4] discussed that position 256 is involved in the
trimeric interface of RANKL and it forms an ionic
interaction with D303 of the neighboring monomer.
Our attempt to restore the ionic bond by making the
reciprocal double mutation K256D/D303K could not
rescue the folding of the protein. More refined studies
on position mRANKL_K256 might still be of interest
as Luan et al. [34] suggested that hRANKL_K257,
which is the equivalent to mRANKL_K256, interacts
with the E95 residue of hOPG-CRD.
Computational Protein Design (CPD) methods have
been successfully used for analyzing and modifying
protein–protein interactions by us [32,35]. Compared
to traditionally directed evolution, which produces and
evaluates mutations at many positions, CPD can guide
us directly to focus on certain key amino acids in a
Fig. 4. Typical SPR sensorgrams obtained
for binding between RANK-Fc/OPG-Fc and
RANKL_WT/RANKL_Q236D. Depicted are
the binding between (A) OPG-Fc and
RANKL_WT, (B) OPG-Fc and
RANKL_Q236D, (C) RANK-Fc and
RANKL_WT, and (D) RANK-Fc and
RANKL_Q236D. Injection of RANKL is
marked with a double-headed arrow. After
injection, the dissociation was followed for
1000 s.
Fig. 5. mRNA levels of different ECM-degrading enzymes, (A) MMP 9 and (B) TRAP, after treatment with RANKL_WT and mutants,
determined by real-time quantitative PCR. Significance was calculated using a Student’s t-test compared to cells treated with RANKL_WT
(50 ngmL1) plus mOPG-Fc (400 ngmL1): (**) is P < 0.01 and (***) is P < 0.0001. The error bars reflect the standard deviation of three
independent experiments.
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much shorter time. Therefore, the combination of
CPD and focused mutagenesis and screening is effi-
cient as exemplified by the mutant Q236D. However,
there are limitations in the predictions given by CPD
and the factual results can differ from predictions as
exemplified by the mutants of residue K256.
Receptor binding experiments using prescreen
ELISA and SPR confirmed the predictions from the
design that residue Q236 is one of the most important
residues for OPG binding. On the basis of the ELISA
results, we purified RANKL_Q236N, Q236S, Q236H,
Q236D, Q236P, Q236K, and Q236A and using SPR
all were shown to have decreased affinity for OPG in
accordance with the in silico predictions. All of them,
except Q236K, have affinities for RANK comparable
to RANKL_WT (Table 2). RANKL_Q236D is the
best among them to have approximately a 30-time
decrease in affinity to OPG-Fc. In line with these
results, structural analysis of this mutation (Fig. 7A,B)
shows that the single substitution at 236 position from
glutamine to aspartate reduces the length of the side
chain. Therefore, the distance from RANKL 236 to
OPG E93 and E95 becomes larger, and two hydrogen
bonds might disappear that are normally present
between RANKL Q236 and OPG residues E93 and
E95. On the other hand, the negatively charged
aspartate on position 236 may have repulsion to the
negatively charged E93 and E95 residues on the OPG
surface. Interestingly, Warren et al. [36] previously
selected RANKL_Q236H from an error-prone PCR
library using yeast display to have a decrease in bind-
ing to OPG. Here, we used saturation mutagenesis and
among others also selected RANKL_Q236H to show
a lower affinity to OPG. Thanks to the saturation
mutagenesis, we selected a superior variant,
RANKL_Q236D, which has a 6.8-time decrease in
affinity to OPG compared to RANKL_Q236H. This
novel variant shows superior properties to initiate the
process of ECM degradation in fibrotic tissue, which is
typified by an excess of OPG [20,24]. In the further
development of this variant towards a therapeutic drug
it should be noted that the RANKL/RANK/OPG
pathway also plays an important role in bone remodel-
ing. Therefore, a tissue-specific delivery of
RANKL_Q236D is needed to achieve targeting of
fibrotic organs directly without influencing the bone
remodeling. As fibrosis can occur in many different
organs showing a common pathogenic pathway and
the presence of matrix proteins is highly similar, it is
suggested that promoting ECM degradation could be
a common way for organ repair [37]. Drug delivery
systems that can target these different organs will be
Fig. 6. Effect of RANKL variants on RANKL induced osteoclastogenesis in RAW 264.7 cells. (A) TRAP activity and (B) relative number of
osteoclasts obtained after treatment of murine RAW 264.7 cells with RANKL variants (50 ngmL1) and RANKL_WT (50 ngmL1) with or
without mOPG-Fc (400 ngmL1). (C) Microscope images of RAW 264.7 cells treated with RANKL_WT and RANKL_Q236D with or without
mOPG-Fc. Scale 100 lm. Significance was calculated using a Student’s t-test: (**) is P < 0.01 and (***) is P < 0.0001. The error bars
reflect the standard deviation of three independent experiments.
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the topic of our future research. As it is crucial and
essential to identify alternative therapeutic strategies
for fibrosis treatment [16,38], we think our approach is
worthwhile pursuing.
In conclusion, we have built a structure-based
RANKL mutant library containing 44 RANKL
mutants and the Q236 residue of RANKL is of impor-
tance for OPG binding. RANKL_Q236D was found
to maintain activating RAW 264.7 cells and to escape
from the obstruction by exogenous OPG. Notably, the
antifibrotic effect of RANKL_Q236D is deserved to be
evaluated in vivo. In our study, the importance of the
RANKL Q236 residue in RANKL–OPG binding and
the discovery of RANKL_Q236D variant form a start-




Binding simulations were performed using the avail-
able 3D structures of murine RANKL–RANK and
RANKL–OPG complexes (Protein Data Bank acces-
sion codes 4GIQ and 4E4D). BIOVIA DISCOVERY STUDIO
4.5 (Accelrys, CA, USA) was used to perform all the
calculations and predictions. Briefly, homotrimer struc-
tures of RANKL–RANK and RANKL–OPG were
prepared and minimized based on CHARMm force
field as previously described [10]. Generalized Born
with molecular volume (GBMW) was used as an
implicit solvation model. Interactions including hydro-
gen bond, electrostatic and hydrophobic effects
between one ligand and two receptors of each complex
were analyzed. Residues of RANKL that showed more
interactions with OPG than RANK were selected to
do further calculations on mutation binding energy
difference. Predicted differences in RANK or OPG
binding energy (DDGi) of the RANKL mutants com-
pared to RANKL_WT were determined through inter-
action energy calculation as previously described [10].
Site-directed mutagenesis, production, and
purification of the RANKL variants
cDNA corresponding to mouse soluble RANKL (aa
160–316) was cloned in pET15b (Novagen, Darmstadt,
Germany) using NcoI and BamHI restriction sites.
Mutants were constructed by QuikChange PCR
method using Phusion high-fidelity DNA polymerase
(New England Biolabs, Ipswich, MA, USA). For full
randomization of each residue, the small-intelligent
method was used by mixing four pairs of
complementary primers with degenerate codons NDT,
VMA, ATG, and TGG at a ratio of 12 : 6 : 1 : 1
[39,40]. The PCR products were digested with DpnI
(Fermentas, St. Leon, Lithuania) enzymes and then
transformed into Escherichia coli DH5a cells. The
colonies were transferred to a 96-well Luria–Bertani
(LB) agar plate with 100 lgmL1 ampicillin and
sequenced by GATC Biotech (Constance, Germany).
After confirming the sequences of mutations, the plas-
mids were transformed into E. coli BL21(DE3) cells
individually. Homotrimeric RANKL proteins were
produced and purified as described before [10]. For
prescreen using ELISA assay, the purities of the
RANKL samples after cation exchange column (SP
column, GE Healthcare, Uppsala, Sweden) were suffi-
cient.
Prescreen ELISA
Murine RANK-Fc (R&D Systems, Minneapolis, MN,
USA) and murine OPG-Fc (Bio Legends, San Diego,
CA, USA) (100 lL, 10 nM) were immobilized on a 96-
well high binding plate (Greiner, Frickenhausen, Ger-
many) by in 0.1 M NaHCO3 (Merck, Darmstadt, Ger-
many) buffer pH 8.6 overnight at 4 °C, respectively.
The wells were subsequently washed with PBS buffer
including 0.05% v/v Tween 20 (PBST; Duchefa, Haar-
lem, the Netherlands), pH 7.4, and the remaining bind-
ing places were blocked with 2% w/v BSA (Roche,
Mannheim, Germany) in PBS, pH 7.4 for 2 h. After
washing for three times, 100 lL of 0.5 nM one-step
purified RANKL_WT or mutants were added and
incubated at room temperature for 1 h. After washing
with TBST buffer, a 1 : 1000 dilution of goat anti-
RANKL antibody (R&D Systems; Cat # BAF462,
Lot # CLR0412011) was added and incubated for 1 h,
and after washing, subsequently incubated with a
1 : 1000 anti-goat HRP-conjugated antibody (Milli-
pore, Billerica, MA, USA). The signal was quantified
using the One-step Turbo TMB reagent (ThermoScien-
tific, Rockford, IL, USA) and stopped by 100 lL of
1 M sulfuric acid solution. The absorbance was mea-
sured at 450 nm. The percentage of RANKL mutants
bound to RANK-Fc or OPG-Fc was measured relative
to the binding of RANKL_WT.
Kinetic analysis by surface plasmon resonance
Binding experiments were determined using a Biacore
3000 system (GE Healthcare) at 25 °C. HBS-P buffer
[10 mM HEPES, pH 7.4, 150 mM NaCl, 0.005% (v/v)
surfactant P20; GE Healthcare] was used as a running
buffer. A CM4 sensor chip (Biacore) was coated with
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protein A (Sigma, Saint Louis, MO, USA) in 10 mM
NaAc, pH 4.5. To achieve trimer–monomer complexes
between ligand and receptors, RANK-Fc (Sigma) and
OPG-Fc (R&D Systems) were captured at a low den-
sity, not exceeding 60 RU, with a flow rate of
50 lLmin1. RANKL was injected subsequently at in
concentrations between 0.01 and 160 nM for 3 min,
followed by a disassociation period for 1000 s. The
chip surface was regenerated by two injections of
10 mM glycine, pH 1.5–2.0 (30 s). The response data
were corrected for buffer effect and was fitted to a
1 : 1 Langmuir model using the BIAEVALUATION soft-
ware version 4.2 (GE Healthcare, Uppsala, Sweden).
Real-time quantitative PCR
Murine RAW 264.7 cells were a kind gift obtained
from J. Doktor (University Medical Center Gronin-
gen, Groningen, the Netherlands). Cells were cultured
in Dulbecco’s modified Eagle’s medium (Life Tech-
nologies, Carlsbad, CA, USA) with 10% v/v FBS (Life
Technologies) and 2 mM penicillin/streptomycin (Life
Technologies). RAW 264.7 cells were seeded at a den-
sity of 2 9 105 cells per well in a 12-well plate (Grei-
ner) and allowed to adhere for overnight. On day 2,
50 ngmL1 RANKL_WT, combination of
50 ngmL1 RANKL_WT plus 400 ngmL1 mOPG-
Fc (R&D) and combinations of 50 ngmL1 RANKL
mutants plus 400 ngmL1 mOPG-Fc were added to
the cells for 24 h.
Cells of each treatment were harvested and total
mRNA was extracted using Maxwell LEX simply
RNA Cells/Tissue kit (Promega, Madison, WI, USA)
according to instruction described. The concentration
of mRNA was measured using Nanodrop ND-100
spectrophotometer (Nanodrop Technologies, Wilming-
ton, DE, USA). cDNA was obtained through a reverse
transcription reaction using M-MLV reverse transcrip-
tase (Promega) and random primers (Promega). The
quantitative real-time PCR was performed using Sensi-
MixTM SYBR kit (Bioline, Taunton, MA, USA) with
the following specific primer sequences: GAPDH, 50-





ward) and 50-TCAGCACATAGCCCACACCG-30 (re-
verse). Thermal cycling and fluorescence detection
were performed using QuantStudio real time PCR Sys-
tem (Thermo Fischer) and Ct values were calculated
using QUANTSTUDIO REAL TIME PCR software v1.3
(Thermo Fischer, Waltham, MA, USA). For each
sample, mRNA expression was normalized to GAPDH
and calculated with the 2DDCt method.
Osteoclast differentiation assay
The biological activities of RANKL_WT and mutants
were evaluated using trap activity assay. RAW 264.7
cells were seeded into a 96-well plate with a density of
2500 cells per well. On day 2, cells were treated with
25 ngmL1 of RANKL with or without 200 ngmL1
of mOPG-Fc. After 4 days of treatment, cells were
washed with PBS buffer and fixed with 4% fomalde-
hyd (Sigma) at 37 °C for 1 h. After washing with PBS
buffer, the cells were then lysed for 5 min with lysis
buffer containing 0.2 M Sodium acetate, 20 mM tar-
taric acid, and 1% triton X-100. After lysis, the plate
was centrifuged for 5 min at 200 g and the super-
natants were removed. The cells were then incubate
with paranitrophenylphosphate (pNPP) solution con-
taining 20 mM pNPP, 0.2 M Sodium acetate, 20 mM
tartaric acid, and 30 mM potassium chloride (100 lL
per well) at 37 °C for 1 h. The reaction was stopped
with 1 M NaOH (100 lL per well) and the absorbance
was measured at 405/410 nm using a microplate reader
(Thermo Labsystems, Beverly, MA, USA). The absor-
bance in the wells containing 25 ngmL1
RANKL_WT was set to 100%.
The osteoclast differentiation assay was performed
as well. As previously described [10], RAW 264.7 cells
were seeded with a density of 1000 cells per well in a
96-well plate. At day 3 and day 5, cells were treated
Fig. 7. Predicted area of interaction of
RANKL and OPG receptor around position
236. (A) RANKL_WT and (B) RANKL_Q236D
variant.
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with 50 ngmL1 of RANKL with or without
400 ngmL1 of mOPG-Fc. At day 7, osteoclast for-
mation was determined using the TRAP staining kit
(Sigma) according to the manufacturer’s instructions.
Multinucleated (three or more nuclei) TRAP-positive
cells were treated as osteoclasts and counted under the
microscope. The number of osteoclasts in the wells
containing 50 ngmL1 RANKL_WT was set to
100%.
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